Cargando…

Biological Scaffolds for Congenital Heart Disease

Congenital heart disease (CHD) is the most predominant birth defect and can require several invasive surgeries throughout childhood. The absence of materials with growth and remodelling potential is a limitation of currently used prosthetics in cardiovascular surgery, as well as their susceptibility...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Amy G., Salih, Tasneem, Ghorbel, Mohamed T., Caputo, Massimo, Biglino, Giovanni, Carrabba, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854830/
https://www.ncbi.nlm.nih.gov/pubmed/36671629
http://dx.doi.org/10.3390/bioengineering10010057
_version_ 1784873223841644544
author Harris, Amy G.
Salih, Tasneem
Ghorbel, Mohamed T.
Caputo, Massimo
Biglino, Giovanni
Carrabba, Michele
author_facet Harris, Amy G.
Salih, Tasneem
Ghorbel, Mohamed T.
Caputo, Massimo
Biglino, Giovanni
Carrabba, Michele
author_sort Harris, Amy G.
collection PubMed
description Congenital heart disease (CHD) is the most predominant birth defect and can require several invasive surgeries throughout childhood. The absence of materials with growth and remodelling potential is a limitation of currently used prosthetics in cardiovascular surgery, as well as their susceptibility to calcification. The field of tissue engineering has emerged as a regenerative medicine approach aiming to develop durable scaffolds possessing the ability to grow and remodel upon implantation into the defective hearts of babies and children with CHD. Though tissue engineering has produced several synthetic scaffolds, most of them failed to be successfully translated in this life-endangering clinical scenario, and currently, biological scaffolds are the most extensively used. This review aims to thoroughly summarise the existing biological scaffolds for the treatment of paediatric CHD, categorised as homografts and xenografts, and present the preclinical and clinical studies. Fixation as well as techniques of decellularisation will be reported, highlighting the importance of these approaches for the successful implantation of biological scaffolds that avoid prosthetic rejection. Additionally, cardiac scaffolds for paediatric CHD can be implanted as acellular prostheses, or recellularised before implantation, and cellularisation techniques will be extensively discussed.
format Online
Article
Text
id pubmed-9854830
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98548302023-01-21 Biological Scaffolds for Congenital Heart Disease Harris, Amy G. Salih, Tasneem Ghorbel, Mohamed T. Caputo, Massimo Biglino, Giovanni Carrabba, Michele Bioengineering (Basel) Review Congenital heart disease (CHD) is the most predominant birth defect and can require several invasive surgeries throughout childhood. The absence of materials with growth and remodelling potential is a limitation of currently used prosthetics in cardiovascular surgery, as well as their susceptibility to calcification. The field of tissue engineering has emerged as a regenerative medicine approach aiming to develop durable scaffolds possessing the ability to grow and remodel upon implantation into the defective hearts of babies and children with CHD. Though tissue engineering has produced several synthetic scaffolds, most of them failed to be successfully translated in this life-endangering clinical scenario, and currently, biological scaffolds are the most extensively used. This review aims to thoroughly summarise the existing biological scaffolds for the treatment of paediatric CHD, categorised as homografts and xenografts, and present the preclinical and clinical studies. Fixation as well as techniques of decellularisation will be reported, highlighting the importance of these approaches for the successful implantation of biological scaffolds that avoid prosthetic rejection. Additionally, cardiac scaffolds for paediatric CHD can be implanted as acellular prostheses, or recellularised before implantation, and cellularisation techniques will be extensively discussed. MDPI 2023-01-02 /pmc/articles/PMC9854830/ /pubmed/36671629 http://dx.doi.org/10.3390/bioengineering10010057 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Harris, Amy G.
Salih, Tasneem
Ghorbel, Mohamed T.
Caputo, Massimo
Biglino, Giovanni
Carrabba, Michele
Biological Scaffolds for Congenital Heart Disease
title Biological Scaffolds for Congenital Heart Disease
title_full Biological Scaffolds for Congenital Heart Disease
title_fullStr Biological Scaffolds for Congenital Heart Disease
title_full_unstemmed Biological Scaffolds for Congenital Heart Disease
title_short Biological Scaffolds for Congenital Heart Disease
title_sort biological scaffolds for congenital heart disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854830/
https://www.ncbi.nlm.nih.gov/pubmed/36671629
http://dx.doi.org/10.3390/bioengineering10010057
work_keys_str_mv AT harrisamyg biologicalscaffoldsforcongenitalheartdisease
AT salihtasneem biologicalscaffoldsforcongenitalheartdisease
AT ghorbelmohamedt biologicalscaffoldsforcongenitalheartdisease
AT caputomassimo biologicalscaffoldsforcongenitalheartdisease
AT biglinogiovanni biologicalscaffoldsforcongenitalheartdisease
AT carrabbamichele biologicalscaffoldsforcongenitalheartdisease